Profile data is unavailable for this security.
About the company
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
- Revenue in USD (TTM)0.00
- Net income in USD-27.95m
- Incorporated2016
- Employees37.00
- LocationAptevo Therapeutics Inc2401 4th Ave Ste 1050SEATTLE 98121-3460United StatesUSA
- Phone+1 (206) 838-0500
- Fax+1 (206) 838-0503
- Websitehttps://aptevotherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alaunos Therapeutics Inc | 6.00k | -4.03m | 6.07m | 1.00 | -- | 2.14 | -- | 1,011.76 | -2.29 | -2.29 | 0.0034 | 1.27 | 0.0017 | -- | -- | 6,000.00 | -110.67 | -63.80 | -145.65 | -77.93 | -- | -- | -67,083.34 | -7,084.74 | -- | -- | 0.00 | -- | 100.00 | -- | 86.68 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -21.97m | 6.13m | 37.00 | -- | 0.1834 | -- | -- | -37.84 | -37.84 | 0.00 | 50.98 | 0.00 | -- | -- | 0.00 | -53.09 | -52.36 | -56.24 | -55.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.22 | -- | -36.69 | -- |
| Mustang Bio Inc | 0.00 | -2.34m | 6.23m | 6.00 | -- | 0.638 | -- | -- | -47.37 | -47.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -17.59 | -70.16 | -224.95 | -83.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 69.47 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -10.85m | 6.29m | 27.00 | -- | -- | -- | -- | -1.50 | -1.50 | 0.00 | -0.6973 | 0.00 | -- | -- | 0.00 | -637.06 | -112.30 | -- | -219.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 32.39 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 3.29m | -10.87m | 6.69m | 16.00 | -- | 1.38 | -- | 2.03 | -17.27 | -17.27 | 5.09 | 3.98 | 0.3025 | 2.74 | 5.08 | 205,752.50 | -100.21 | -73.55 | -191.77 | -123.30 | 43.08 | -- | -331.26 | -476.22 | 0.7618 | -- | 0.0392 | -- | -1.90 | 74.49 | -4.06 | -- | -- | -- |
| Creative Medical Technology Holdings Inc | 6.00k | -5.96m | 6.74m | 4.00 | -- | 0.8907 | -- | 1,124.12 | -2.87 | -2.87 | 0.0027 | 2.17 | 0.0009 | 1.10 | -- | 1,500.00 | -93.58 | -83.62 | -98.14 | -- | 60.00 | 62.58 | -99,356.66 | -10,541.10 | 20.70 | -- | 0.00 | -- | 22.22 | -41.85 | -3.91 | -- | -- | -- |
| Aptorum Group Ltd | -100.00bn | -100.00bn | 6.83m | 1.00 | -- | 0.2661 | -- | -- | -- | -- | -- | 3.15 | -- | -- | -- | -- | -- | -33.06 | -- | -31.53 | -- | 1.65 | -- | -1,009.86 | -- | -- | 0.2079 | -- | -100.00 | -- | -51.09 | -- | -- | -- |
| Theriva Biologics Inc | 0.00 | -26.19m | 6.92m | 22.00 | -- | 0.2967 | -- | -- | -5.53 | -5.53 | 0.00 | 0.6539 | 0.00 | -- | -- | 0.00 | -73.83 | -37.94 | -99.55 | -42.02 | -- | -- | -- | -- | -- | -- | 0.2025 | -- | -- | -- | -39.81 | -- | -- | -- |
| Aptevo Therapeutics Inc | 0.00 | -27.95m | 6.96m | 37.00 | -- | 0.3079 | -- | -- | -306,220.00 | -306,220.00 | 0.00 | 22.67 | 0.00 | -- | -- | 0.00 | -125.64 | -47.17 | -172.77 | -82.66 | -- | -- | -- | -487.43 | -- | -- | 0.00 | -- | -- | -- | -29.38 | -- | -- | -- |
| Synlogic Inc | 0.00 | -3.23m | 7.17m | 1.00 | -- | 0.6949 | -- | -- | -0.2625 | -0.2625 | 0.00 | 0.8826 | 0.00 | -- | -- | 0.00 | -17.30 | -44.41 | -27.54 | -50.06 | -- | -- | -- | -3,944.49 | -- | -- | 0.00 | -- | -99.76 | -67.55 | 61.88 | -- | -59.28 | -- |
| Alzamend Neuro Inc | 0.00 | -6.47m | 7.30m | 4.00 | -- | 1.67 | -- | -- | -5.71 | -5.71 | 0.00 | 1.15 | 0.00 | -- | -- | 0.00 | -116.49 | -171.97 | -144.76 | -256.71 | -- | -- | -- | -- | -- | -766.93 | 0.00 | -- | -- | -- | 48.68 | -- | -- | -- |
| Curative Biotechnology Inc | 0.00 | -6.02m | 7.75m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
| Aclarion Inc | 67.48k | -7.39m | 7.79m | 6.00 | -- | 0.1272 | -- | 115.48 | -1,687.50 | -1,687.50 | 0.1948 | 21.46 | 0.0082 | -- | 2.76 | 11,246.67 | -89.50 | -- | -97.72 | -- | -7.85 | -- | -10,868.49 | -- | -- | -25,428.22 | 0.00 | -- | -39.36 | -- | -43.60 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Yorkville Advisors LLCas of 16 Jun 2025 | 19.88k | 2.12% |
| Point72 Asset Management LPas of 30 Sep 2025 | 16.66k | 1.78% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 12.71k | 1.36% |
| DRW Securities LLCas of 30 Sep 2025 | 7.31k | 0.78% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 4.14k | 0.44% |
| Virtu Americas LLCas of 30 Sep 2025 | 2.13k | 0.23% |
| Abante Asesores Gesti�n SGIIC SAas of 31 Dec 2025 | 1.76k | 0.19% |
| Focus Partners Wealth LLCas of 30 Sep 2025 | 556.00 | 0.06% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2025 | 361.00 | 0.04% |
| UBS Switzerland AG (Investment Management)as of 31 Dec 2025 | 160.00 | 0.02% |
